Biocon Biologics partners with Sandoz for distribution of its biosimilar to treat immune-related diseases in Japan
时间:2024-06-26 13:43:19 阅读(143)
Biocon Biologics Ltd on Friday signed a Distribution Agreement with Sandoz, granting the Company the exclusive rights to promote, sell and distribute th injection of Adalimumab BS in Japan.
“Based on this Agreement, Viatris has completed marketing and promotion of the product as of December 15, 2023, but will continue to provide transition support until Sandoz will gradually assume responsibilities for the product starting February 15, 2024. Biocon Biologics has acquired the global biosimilars portfolio of Viatris including Adalimumab. Fujifilm Kyowa Kirin Biologics Co. Ltd., the developer of the drug, has concluded an exclusive global marketing license agreement with Biocon Biologics Ltd affiliate,” the company said in a statement.
“Sandoz is committed to further strengthening its product pipeline to drive sustainable business growth,” it added.
The transfer of the distribution rights of this product is part of this strategy, and its addition to the product portfolio will strengthen Sandoz’s immunology and biosimilar portfolio.
Biocon Biologics recently announced the successful completion of its integration of the acquired Viatris’ biosimilars business in 120 countries ahead of schedule, marking a significant milestone in the Company’s journey as a fully integrated, global biosimilars enterprise. At a global level, Biocon Biologics has a robust pipeline of 20 assets for diabetology, oncology, immunology, and ophthalmology.
猜你喜欢
- US Stocks- Futures muted after jobs data raises odds of more rate hikes
- Will Nifty continue to trade above 19800 or fall in trade- See GIFT Nifty, FII data, F&O ban, crude, more before market opens
- US stocks- Wall Street set to fall on aggressive rate hike worries
- Will Nifty hold 21,500 levels or Hit a new high of 22,000- See GIFT Nifty, FII data, F&O ban, crude, more before market opens
- US Stocks- Growth stocks drag Wall Street lower on rate hike worries
- World Bank retains India growth forecasts for FY24 and FY25
- 6 key themes to help India’s corporate earnings beat emerging markets; check preferred sector stocks to buy
- 5 dead as Japan Airlines plane burst into flames after massive collision at Tokyo Airport - Watch
- Will Nifty breach 19550 or give up gains- See GIFT Nifty, FII data, F&O ban, crude, more before market opens